NCT07532928Enrolling by invitation
A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
Based on multimodal data, the investigators establish a dynamic deep learning model to conduct prognostic risk assessment for patients and recommend the 'most suitable' treatment/follow-up regimen after radical treatment, assisting clinicians in improving homogenized evaluation levels and achieving individualized precision therapy, thereby providing scientific evidence for the currently widely debated selection of postoperative adjuvant therapy in locally advanced head and neck squamous cell carcinoma patients.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 571 (estimated)
- First submitted
- 8 Apr 2026
- Start date
- 15 Aug 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Head and neck cancer
- NCT number
- NCT07532928
What you commit to
- Study type: Observational
- Planned participants: 571
- From 15 Aug 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of or coexisting secondary malignancies.
Other
- Lack of definitive radical treatment.
- Absence of baseline or follow-up imaging (MRI/CT/PET-CT).
- Investigator-determined unsuitability for study participation.
Who the study is looking for
- Age \>= 18 years.
- Patients diagnosed and treated at Nanfang Hospital, Southern Medical University or its cooperative hospitals between January 2017 and December 2025.
- Patients who either seek medical treatment after June 2022 or sought medical treatment before that but have not lost contact with the hospital for more than 1 year are required to sign the informed consent form voluntarily.
- Newly diagnosed head and neck squamous cell carcinoma (HNSCC) confirmed by histopathology.
- Locally advanced disease without distant metastasis.
- Complete clinical data (including patient demographics, tumor characteristics, treatment details, and prognostic variables).
- Availability of MRI, CT, or PET-CT images before and after radical treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology, Nanfang Hospital, Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.